Literature DB >> 12583820

Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice.

K Stein1, K Dalziel, A Walker, L McIntyre, B Jenkins, J Horne, P Royle, A Round.   

Abstract

Mesh：

Year:  2002        PMID： 12583820

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  15 in total

1.  Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Authors:  Benjamin P Linas; Angela Y Wong; Bruce R Schackman; Arthur Y Kim; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

2.  The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Authors:  Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim
Journal:  Ann Intern Med       Date:  2015-05-05       Impact factor: 51.598

3.  The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.

Authors:  Benjamin P Linas; Devra M Barter; Jared A Leff; Madeline DiLorenzo; Bruce R Schackman; Charles R Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Kenneth A Freedberg
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.632

4.  Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.

Authors:  Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas
Journal:  Addiction       Date:  2015-01       Impact factor: 7.256

5.  Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.

Authors:  Sarah Gutkind; Bruce R Schackman; Jake R Morgan; Jared A Leff; Linda Agyemang; Sean M Murphy; Matthew J Akiyama; Brianna L Norton; Alain H Litwin; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 20.999

6.  Optimal timing of hepatitis C treatment among HIV/HCV coinfected ESRD patients: Pre- vs posttransplant.

Authors:  Brittany A Shelton; Gideon Berdahl; Deirdre Sawinski; Benjamin P Linas; Peter P Reese; Margaux N Mustian; Rhiannon D Reed; Paul A MacLennan; Jayme E Locke
Journal:  Am J Transplant       Date:  2019-01-25       Impact factor: 9.369

7.  Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation.

Authors:  Brittany A Shelton; Deirdre Sawinski; Benjamin P Linas; Peter P Reese; Margaux Mustian; Mitch Hungerpiller; Rhiannon D Reed; Paul A MacLennan; Jayme E Locke
Journal:  Am J Transplant       Date:  2018-08-30       Impact factor: 9.369

8.  Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison.

Authors:  Andrew J Sutton; W John Edmunds; O Noel Gill
Journal:  BMC Public Health       Date:  2006-06-27       Impact factor: 3.295

9.  Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.

Authors:  Sabrina A Assoumou; Abriana Tasillo; Jared A Leff; Bruce R Schackman; Mari-Lynn Drainoni; C Robert Horsburgh; M Anita Barry; Craig Regis; Arthur Y Kim; Alison Marshall; Sheel Saxena; Peter C Smith; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 20.999

10.  'I just keep thinking I haven't got it because I'm not yellow': a qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners.

Authors:  Fu-Meng Khaw; Lynne Stobbart; Madeleine J Murtagh
Journal:  BMC Public Health       Date:  2007-06-07       Impact factor: 3.295
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.